• High-affinity, fully human, PD-L1-specific IgG4 monoclonal antibody that inhibits the binding of PD-L1 to both PD-1 and CD80
    • No active clinical trials for cancer in the United States; previous studies in melanoma and hematologic malignancies were withdrawn.
    • Recommended dose: 0.3 to 10 mg/kg as 60-minute infusion every 2 weeks
    • Half-life: â™15 days
    • Common side effects: Rash, hypothyroidism, hepatitis, diarrhea
    (Brahmer et al., 2012)
    Other topics in Targeted and Immunotherapy Agents